Advanced

Identification of serum biomarker signatures associated with pancreatic cancer

Wingren, Christer LU ; Sandström Gerdtsson, Anna LU ; Segersvard, R.; Carlsson, Anders LU ; Andersson, Roland LU ; Lohr, M. and Borrebaeck, Carl LU (2012) In Cancer Research 72. p.90-2481
Abstract
Pancreatic cancer is an aggressive disease with poor prognosis, due, in part, to the lack of disease-specific biomarkers that could afford early and accurate diagnosis. With a recombinant antibody microarray platform, targeting mainly immunoregulatory proteins, we screened sera from 148 patients with pancreatic cancer, chronic pancreatitis, autoimmune pancreatitis (AIP), and healthy controls (N). Serum biomarker signatures were derived from training cohorts and the predictive power was evaluated using independent test cohorts. The results identified serum portraits distinguishing pancreatic cancer from N [receiver operating characteristics area under the curve (AUC) of 0.95], chronic pancreatitis (0.86), and AIP (0.99). Importantly, a... (More)
Pancreatic cancer is an aggressive disease with poor prognosis, due, in part, to the lack of disease-specific biomarkers that could afford early and accurate diagnosis. With a recombinant antibody microarray platform, targeting mainly immunoregulatory proteins, we screened sera from 148 patients with pancreatic cancer, chronic pancreatitis, autoimmune pancreatitis (AIP), and healthy controls (N). Serum biomarker signatures were derived from training cohorts and the predictive power was evaluated using independent test cohorts. The results identified serum portraits distinguishing pancreatic cancer from N [receiver operating characteristics area under the curve (AUC) of 0.95], chronic pancreatitis (0.86), and AIP (0.99). Importantly, a 25-serum biomarker signature discriminating pancreatic cancer from the combined group of N, chronic pancreatitis, and AIP was determined. This signature exhibited a high diagnostic potential (AUC of 0.88). In summary, we present the first prevalidated, multiplexed serum biomarker signature for diagnosis of pancreatic cancer that may improve diagnosis and prevention in premalignant diseases and in screening of high-risk individuals. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Pancreatic Neoplasms/*blood, Middle Aged, Humans, Pancreatic Ductal/*blood, Carcinoma, Biological Markers/blood, 80 and over, Aged, Adolescent, Adult, Pancreatitis/diagnosis, Pancreatitis, Chronic/blood, Tumor Markers, Biological/*blood
in
Cancer Research
volume
72
pages
90 - 2481
publisher
American Association for Cancer Research
external identifiers
  • wos:000307346800004
  • scopus:84861176020
ISSN
1538-7445
DOI
10.1158/0008-5472.CAN-11-2883
project
CREATE Health
language
English
LU publication?
yes
id
d71cc3f3-0a9b-41a1-962c-97e7298a7e1a (old id 4146679)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22589272
date added to LUP
2013-11-19 10:24:03
date last changed
2017-05-14 04:30:08
@article{d71cc3f3-0a9b-41a1-962c-97e7298a7e1a,
  abstract     = {Pancreatic cancer is an aggressive disease with poor prognosis, due, in part, to the lack of disease-specific biomarkers that could afford early and accurate diagnosis. With a recombinant antibody microarray platform, targeting mainly immunoregulatory proteins, we screened sera from 148 patients with pancreatic cancer, chronic pancreatitis, autoimmune pancreatitis (AIP), and healthy controls (N). Serum biomarker signatures were derived from training cohorts and the predictive power was evaluated using independent test cohorts. The results identified serum portraits distinguishing pancreatic cancer from N [receiver operating characteristics area under the curve (AUC) of 0.95], chronic pancreatitis (0.86), and AIP (0.99). Importantly, a 25-serum biomarker signature discriminating pancreatic cancer from the combined group of N, chronic pancreatitis, and AIP was determined. This signature exhibited a high diagnostic potential (AUC of 0.88). In summary, we present the first prevalidated, multiplexed serum biomarker signature for diagnosis of pancreatic cancer that may improve diagnosis and prevention in premalignant diseases and in screening of high-risk individuals.},
  author       = {Wingren, Christer and Sandström Gerdtsson, Anna and Segersvard, R. and Carlsson, Anders and Andersson, Roland and Lohr, M. and Borrebaeck, Carl},
  issn         = {1538-7445},
  keyword      = {Pancreatic Neoplasms/*blood,Middle Aged,Humans,Pancreatic Ductal/*blood,Carcinoma,Biological Markers/blood,80 and over,Aged,Adolescent,Adult,Pancreatitis/diagnosis,Pancreatitis,Chronic/blood,Tumor Markers,Biological/*blood},
  language     = {eng},
  pages        = {90--2481},
  publisher    = {American Association for Cancer Research},
  series       = {Cancer Research},
  title        = {Identification of serum biomarker signatures associated with pancreatic cancer},
  url          = {http://dx.doi.org/10.1158/0008-5472.CAN-11-2883},
  volume       = {72},
  year         = {2012},
}